Multhoff G, Seier S, Stangl S, Sievert W, Shevtsov M, Werner C, Pockley AG, Blankenstein C, Hildebrandt M, Offner R, Ahrens N, Kokowski K, Hautmann M, Roedel C, Fietkau R, Lubgan D, Huber R, Hautmann H, Duell T, Molls M, Specht H, Haller B, Devecka M, Sauter A, Combs SE (2020)
Publication Type: Journal article
Publication year: 2020
Book Volume: 26
Pages Range: 5368-5379
Journal Issue: 20
DOI: 10.1158/1078-0432.CCR-20-1141
Purpose: Non-small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. Amembrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-30) explores tolerability and efficacy of ex vivo-activated NK cells in patients with NSCLC after radiochemotherapy (RCT).
APA:
Multhoff, G., Seier, S., Stangl, S., Sievert, W., Shevtsov, M., Werner, C.,... Combs, S.E. (2020). Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial. Clinical Cancer Research, 26(20), 5368-5379. https://doi.org/10.1158/1078-0432.CCR-20-1141
MLA:
Multhoff, Gabriele, et al. "Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial." Clinical Cancer Research 26.20 (2020): 5368-5379.
BibTeX: Download